Results of NHS Study

RNS Number : 5687F

Deltex Medical Group PLC

14 January 2010

 



Deltex Medical Group plc

New guidance to NHS hospitals on how and why to adopt ODM

14 January 2010 - Deltex Medical Group plc ("Deltex Medical" or the "Company"), the global leader in oesophageal Doppler monitoring ("ODM"), notes the launch today of a UK government agency's guide on how to procure and implement ODM in NHS hospitals.

The 'How to Why to' guide "Doppler Guided Intraoperative Fluid Management" has today been published online by the NHS National Technology Adoption Centre ('NTAC') at http://www.technologyadoptionhub.nhs.uk/how-to-why-to-guides.html. It gives detailed guidance to NHS hospitals on how to introduce ODM into wide-scale use.

The methodologies and figures included in the 'How to Why to' guide published today by the NHS National Technology Adoption Centre (NTAC) are based on the results of the procurement and implementation of ODM at three different hospitals: Manchester Royal Infirmary, Derby General Hospital and the Whittington Hospital in North London. The 'How to Why to guide' details the clinical, operational and financial effects at these hospitals and sets out a business case for other NHS hospitals to introduce ODM.

Results from 1,247 patients included in the project include a greater than 50% reduction in mortality rate and a three day reduction in length of hospital stay.

Ewan Phillips, Deltex Medical's chief executive, commented:

"The 'How to' part of NTAC's report provides hospitals with a comprehensive guide on how to purchase and implement ODM effectively. We believe this guide will be a valuable resource to NHS hospitals as they strive to provide better quality care at reduced cost.

"The 'Why to' part includes the largest ever dataset on the impact of adopting ODM and confirms the improved patient outcomes and reduced costs shown previously by randomised controlled trials and health technology assessments. NTAC's results establish unequivocally that using ODM during surgery helps to save lives."

For further information, please contact:-

Deltex Medical Group plc            01243 774 837

Nigel Keen, Chairman                    [e-mail]

Ewan Phillips, Chief Executive        [e-mail]

Paul Mitchell, Finance Director       [e-mail]

Nominated Adviser & Broker

Arden Partners plc                      020 7614 5900

Chris Hardie                                 [e-mail]

Matthew Armitt                             [e-mail]

Kreab Gavin Anderson               020 7554 1400

Deborah Walter                            [e-mail]

Robert Speed                               [e-mail]

  Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODM™ monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier.

The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay.

There are already nearly 2,000 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 200 clinical publications on the use of the CardioQ-ODM which have repeatedly:-

• Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works

• Proved that the CardioQ-ODM works in a wide range of surgical procedures

• Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients.

The SupraQ™ is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.

 

END

 

 

MSCGGUGGGUPUGWC